Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.

Abstract

The presence of resistance mutations in patients failing tipranavir or darunavir was examined at the national drug resistance database of the Spanish AIDS Research Network. Although mutations emerging during tipranavir and darunavir failures differed considerably, cross-resistance was found in up to half of the patients tested. Interestingly, mutation 54L, which is associated with tipranavir hypersusceptibility, was selected in half of the darunavir failures. Thus, resistance testing seems mandatory to ensure the benefit of the sequential use of these drugs.

• Authors: Eva Poveda, Lourdes Anta, José Luis Blanco, José Luis Casado, Félix Gutiérrez, Federico García, Juan Luis Gómez-Sirvent, José Antonio Iribarren, Vincent Soriano, Carmen de Mendoza, Resistance Platform of the Spanish AIDS Research Network (ResRIS)
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 54 Issue 7 Pg. 3018-20 (Jul 2010) ISSN: 1098-6596 [Electronic] United States
• PMID: 20479204 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• HIV Protease Inhibitors
• Pyridines
• Pyrones
• Sulfonamides
• Darunavir
• tipranavir

Topics

• Darunavir
• Databases, Factual
• Drug Resistance, Viral (genetics)
• HIV Infections (drug therapy, genetics)
• HIV Protease Inhibitors (therapeutic use)
• Humans
• Mutation
• Pyridines (therapeutic use)
• Pyrones (therapeutic use)
• Spain
• Sulfonamides (therapeutic use)